Lycopene-rich diets modulate HDL functionality and associated inflammatory markers without affecting lipoprotein size and distribution in moderately overweight, disease-free, middle-aged adults: A randomized controlled trial

Jane McEneny¹, Sarah-Louise Henry¹, Jayne Woodside¹, Susan Moir², Amelia Rudd², Nick Vaughan² and Frank Thies²*

¹School of Medicine, Dentistry and Biomedical Sciences, Centre for Public Health, Queen University, Belfast, United Kingdom, ²School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, United Kingdom

Background: The consumption of lycopene-rich foods may lower cardiovascular disease (CVD) risk. Lycopene circulates in the blood bound to lipoproteins, including high-density lipoproteins (HDLs). Preliminary data from our group showed that increased consumption of tomato-based food or lycopene supplement in middle-aged subjects led to functional changes to HDL's sub-fractions, HDL₂ and HDL₃. These changes were also associated with a decrease in serum amyloid A (SAA), potentially enhancing their anti-atherogenic properties.

Objective: We carried out a comprehensive randomized controlled intervention trial with healthy middle-aged volunteers to assess whether the consumption of tomato-based foods or lycopene supplements affects HDL functionality and associated inflammatory markers, and lipoprotein subfractions size and distribution.

Design: Volunteers (225, aged 40–65 years) were randomly assigned to one of three dietary intervention groups and asked to consume a control diet (low in tomato-based foods, <10 mg lycopene/week), a lycopene-rich diet (224–350 mg lycopene/week), or the control diet with a lycopene supplement (70 mg lycopene/week). HDL₂ and HDL₃ were isolated by ultracentrifugation. Compliance was monitored by assessing lycopene concentration in serum. Systemic and HDL-associated inflammation was assessed by measuring SAA concentrations. HDL functionality was determined by monitoring paraoxonase-1 (PON-1), cholesteryl ester transfer protein (CETP), and lecithin cholesterol acyltransferase (LCAT) activities. The lipoprotein subfractions profile was assessed by NMR.
Results: Lycopene in serum and HDL significantly increased following consumption of both the high tomato diet and lycopene supplement (p ≤ 0.001 for both). Lycopene, either as a tomato-rich food or a supplement, enhanced both serum- and HDL₃-PON-1 activities (p ≤ 0.001 and p = 0.036, respectively), while significantly reducing HDL₃-SAA-related inflammation (p = 0.001). Lycopene supplement also significantly increased HDL₃-LCAT activity (p = 0.05), and reduced the activity of both HDL₂- and HDL₃-CETP (p = 0.005 and p = 0.002, respectively). These changes were not associated with changes in the subclasses distribution for all lipoprotein fractions or the size of lipoprotein subclasses.

Conclusion: Our results showed that dietary lycopene can significantly enhance HDL functionality, without associated changes in particle size and distribution, by modulating the activity of HDL-associated enzymes. Concomitantly, dietary lycopene significantly decreased serum- and HDL₃-associated SAA, confirming that SAA may represent a sensitive inflammatory biomarker to dietary change.

Clinical Trial Register: (https://www.isrctn.com), ISRCTN34203810.

KEYWORDS
lycopene, high density lipoprotein, functionality, serum amyloid A, dietary intervention, tomato-rich diet

Introduction

Results from observational studies (1–4) have shown inverse associations between the consumption of tomato or lycopene and the risk of cardiovascular disease (CVD) and related mortality. However, intervention studies with tomato-based products or lycopene supplements focusing on conventional and non-conventional markers of CVD risk have generated inconsistent results. Some trials have shown that lycopene can reduce pro-inflammatory mediators and oxidative stress (5), and modulate some cardiovascular markers (6), namely, blood pressure (7), and lipid profile (8). Other studies, however, found no significant effects on blood lipids (9, 10) and blood pressure (11). A recent systematic review reported no significant differences between lycopene intervention and control groups for blood pressure and lipids (total cholesterol, low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and triglycerides), even in subgroup analyses for individuals with elevated risk factor concentrations at baseline (12). Results from a comprehensive intervention trial carried out in our group showed no effect of a 12-week intervention with a tomato-rich diet (35–50 mg lycopene/day) or lycopene supplement (10 mg/day) on conventional CVD risk markers (13). However, preliminary analysis in a subgroup of the participant from that study showed that increased lycopene intake using supplements or by dietary means over 12 weeks reduced serum amyloid A (SAA) content in serum and HDL. These changes were associated with a concomitant improvement in HDL functionality, as measured by the activity of HDL-associated enzymes such as paraoxonase 1 (PON-1), lecithin cholesterol acyl transferase (LCAT), and cholesterol ester transfer protein (CETP), potentially enhancing HDL anti-atherogenic properties (14), suggesting novel mechanisms by which lycopene could exert cardiovascular protection. Indeed, numerous studies have identified an inverse relationship between HDL concentration and CVD risk (15, 16). HDL, in addition to its central role in the reverse transport of cholesterol, has important antioxidant and anti-inflammatory properties. The lowering of SAA we observed in our subgroup analysis is particularly interesting, as SAA in HDL renders these lipoprotein particles dysfunctional (17, 18), with a reduction of PON-1 and LCAT activities (19, 20). However, these results needed to be confirmed in the full sample size. Furthermore, whether these changes are associated with changes in lipoprotein classes distribution and size remained to be determined.

Methods

Study population

The study was approved by the North of Scotland Research Ethics Committee (07/S0801/32) and conducted in concordance with CONSORT Guidelines (21) and details of the study design
and CONSORT flow diagram have been previously published (13). We conducted a 16-week intervention trial involving 225 healthy men and women (40–65 years, 18.5 < BMI < 35 kg/m², sedentary or moderately active) randomized into three treatment groups: a control diet group (equivalent to 70 mg lycopene per week), a lycopene-rich diet group (high in tomato-based food and equivalent to 224–350 mg lycopene per week), and a lycopene supplement group (equivalent to 70 mg lycopene per week). Each of the diets was practical and realistic for individuals to achieve, with minor alterations to their usual lifestyle. Participants were provided with tomato-based products widely available from the main UK food retailers. Aside from the tomato servings supplied to the participant, the participants were instructed not to alter their food intake, apart from the prescribed changes, and to maintain their usual level of physical activity and lifestyle. Tomato-based food intake was restricted in the lycopene-supplemented group and the control group. All volunteers were not allowed to consume any of the forbidden foods listed below, but were able to consume up to 1 portion of tomato soup, tomato juice, or tomato sauce per week, and either (a) up to 4 raw tomatoes/24 cherry tomatoes per week or (b) up to 1 portion of tomato ketchup per week. Forbidden foods included pasta; canned tomatoes; cooked tomatoes; tomato paste; tomato puree; pizza; salsa; chutney; canned beans/spaghetti/ravioli, etc., in tomato sauce; barbecue sauce; brown sauce; pink grapefruit; guava; watermelon or apricots. Following a 4-week run-in period in which all participants consumed the control diet, volunteers were assigned to one of the above three groups for 12 weeks. Compliance was determined by analysis of serum lycopene concentration and by assessing the consumption of tomato-based foods through the use of a food diary at baseline, during the intervention, and at the end of the intervention. Individuals with signs of the metabolic syndrome, e.g., if they had moderate hypercholesterolemia. Individuals were excluded if they suffered from CVD, diabetes, or asthma, or if they had moderate hypercholesterolemia. Subjects taking any medication known to affect any dependent variable being measured, those with a high habitual intake of tomato-based food (> 5 servings per week) or those regularly consuming nutritional supplements were also excluded. All measurements were performed four times, before the run-in period, at baseline, during, and after the intervention. The samples obtained from the volunteers were anonymized and coded, and the people who assessed the outcomes (research assistants) were blinded after assignment to interventions. During each visit, fasting blood samples were collected, and weight, waist circumference, and blood pressure were measured. Compliance was assessed by measuring serum lycopene concentrations and by analyzing a weekly checklist of tomato-based foods consumed.

Isolation of serum HDL subfractions

HDL₂ and HDL₃ were isolated from serum by rapid ultracentrifugation as previously described (22), using a three-step procedure; a crude (c) HDL was isolated by a 2-h rapid sedimentation method, and then subfractionated into HDL₂ and HDL₃ by two, 2-h sequential rapid flotation ultracentrifugation procedures. The concentrations of HDL₂ and HDL₃-associated total protein, apolipoprotein A1 (apoA1), and SAA were reported using a dilution factor due to the process whereby the subfractions were isolated from serum. Initially, 1.2 ml serum/plasma was used to isolate the HDL subfractions, and collectively, 1.6 ml of sample was retrieved (0.8 ml HDL₂ plus 0.8 ml HDL₃). Taking into consideration the initial volume and volumes retrieved (1.2 ml/1.6 ml), the dilution factor applied to non-standardized (absolute) HDL₂ and HDL₃ concentrations was 1.33.

Lycopene concentration

Lycopene concentration was measured in serum and HDL₂ and HDL₃ by reverse-phase high-performance liquid chromatography as previously described (23).

ApoAI, SAA, IL-6, and hsCRP determination

Apolipoprotein A1 (apoA1) concentration in the HDL subfractions (HDL₂ and HDL₃) was determined using single radial immunodiffusion as previously described (24). SAA, in serum and associated with HDL₂ and HDL₃, was analyzed by an ELISA (Invitrogen UK, KHA0011), as per the manufacturer’s instructions. Analysis was performed using a Grifols TRITURUS system (Italy). Interleukin-6 (IL-6) was determined by ELISA (R&D Systems). High-sensitivity C-reactive protein (hsCRP) was measured at the Department of Clinical Biochemistry at Aberdeen Royal Infirmary using a standardized automated procedure (Behring nephelometry system).

Protein concentration

Protein concentration within HDL₂ and HDL₃ was determined spectrophotometrically using the Biorad assay (BioRad 500-006, Biorad Hemel Hempstead, UK) as per the manufacturer’s instructions. Total protein concentration was...
utilized to standardize SAA, PON-1, CETP, and LCAT within HDL\textsubscript{2} and HDL\textsubscript{3}.

**PON-1, LCAT, and CETP activities**

Paraoxonase-1 (PON-1) activity was measured by monitoring the hydrolysis of phenylacetate using a modification of the method of Hasselwander et al. (25) as previously described (14). The activity of CETP and LCAT was measured in HDL\textsubscript{2} and HDL\textsubscript{3} using commercially available fluorometric assays, as per the manufacturer's instructions (CETP catalog no. RB-CETP; LCAT catalog no. RB-LCAT; Roar Biomedical, NY, USA).

**Determination of lipoprotein classes concentration and size distribution by NMR**

During each visit, 12-h fasted blood samples were taken from the antecubital fossa vein. Serum was prepared after centrifuging blood samples at 800 g at 4\textdegree C for 15 min and stored at −80\textdegree C until analysis. All samples were analyzed in a single batch to reduce variability. Very low-density lipoprotein (VLDL), LDL, and HDL subclasses concentrations and size in serum were determined by NMR (Liposcience Inc., Raleigh, USA). Data on intermediate-density lipoprotein (22.7–27 nm) are not reported in this article. The diameter range of the lipoprotein subclasses is shown in Table 1.

**Results**

**Subject characteristics**

Baseline characteristics of the participants were comparable with regard to age, body mass index, blood pressure, and arterial stiffness (Table 1). More women than men were recruited; however, the proportion of women was similar in all the three groups. The slight imbalance in the number of subjects allocated per group was previously discussed (13).

**Lycopene concentration in serum and HDL subfractions**

Serum lycopene concentration was similar across the groups at baseline, but significantly increased after 12-week intervention in both high tomato and lycopene supplement groups, compared to the low tomato group (13). Lycopene concentration in HDL\textsubscript{2} and HDL\textsubscript{3} subfractions was similar across the groups (p > 0.05, Table 2). Within-group analysis showed that lycopene content in HDL\textsubscript{2} significantly increased following the high tomato diet (p < 0.001) compared to baseline. However, these changes were not significantly different compared to those observed in the other groups (p = 0.294). Both lycopene interventions significantly increased lycopene concentration in HDL\textsubscript{3} by 54.7 and 23.4\% for the tomato-rich diet and lycopene supplement, respectively, compared to the low tomato group (p = 0.005).

**Protein, apoA1, CRP, and SAA concentrations in serum and HDL fractions**

Total protein and apoA1 in HDL\textsubscript{2} and HDL\textsubscript{3} were similar at baseline and remained unchanged after intervention in all the groups (not shown). None of the interventions affected hsCRP serum concentrations (13). However, serum hsCRP and SAA concentrations were significantly positively associated at baseline (Spearman’s rho 0.513, p < 0.001). A similar association was observed between serum hsCRP and HDL\textsubscript{3}-SAA concentrations (Spearman’s rho = 0.438, p < 0.001). These positive associations were also retained after each intervention. The effect of the interventions on SA concentrations in serum and HDL subfractions is shown in Table 3. Serum-SAA concentration was similar across the groups at baseline, but significantly decreased by 12\% following a 12-week intervention with lycopene supplement compared with the other groups (p = 0.046). None of the interventions significantly affected SAA levels in HDL\textsubscript{2}. However, HDL\textsubscript{3}-SAA concentration...
TABLE 2 Participant characteristics at baseline, by the intervention group.

|                           | High Tomato | Lycopene | Control | \(p^b\) |
|---------------------------|-------------|----------|---------|---------|
| Age (years)               | 51.0 (0.7)  | 51.1 (0.9) | 51.1 (0.7) | 0.889   |
| Sex (n)                   |             |          |         |         |
| Men                       | 35          | 28       | 30      | 0.878   |
| Women                     | 46          | 40       | 46      |         |
| Current smokers (n)       | 5           | 6        | 1       |         |
| BMI (kg/m\(^2\))         | 26.4 (0.5)  | 26.7 (0.5) | 26.8 (0.5) | 0.831   |
| Waist circumference (cm)  | 88.1 (1.2)  | 89.0 (1.4) | 88.2 (1.3) | 0.907   |
| Systolic BP (mm Hg)       | 129.4 (1.8) | 130.8 (2.1) | 130.8 (1.7) | 0.953   |
| Diastolic BP (mm Hg)      | 78.8 (1.4)  | 79.6 (1.3) | 79.0 (1.1) | 0.380   |
| Pulse wave velocity (m/s) | 8.20 (0.25) | 8.34 (0.29) | 8.32 (0.19) | 0.605   |
| Stiffness index (m/s)     | 8.2 (0.3)   | 7.7 (0.3)  | 7.6 (0.2)  | 0.272   |
| Alcohol (g/day)           | 12.0 (1.2)  | 11.1 (1.2) | 13.0 (1.4) | 0.479   |

\(^a\)BP, blood pressure; BMI, body mass index.  
\(^b\)Differences between groups were assessed by using two-factor ANOVA (\(p < 0.05\)).  
\(^c\)Mean (SEM) (all such values).  
\(^d\)Calculated by using pulse contour analysis.  
\(^e\)Pearson’s chi-squared test.

significantly decreased (\(p < 0.001\)) in the lycopene supplement (−25.7%) and high tomato (−8.3%) groups, compared with the low tomato group, for which HDL\(_3\)-SAA concentration significantly increased after intervention from baseline.

PON, LCAT, and CETP in HDL fractions

The effects of the interventions on PON-1, LCAT, and CETP activities in HDL fractions are summarized in Tables 4–6, respectively. At baseline, PON-1 and LCAT activities were similar for both HDL\(_2\) and HDL\(_3\) fractions while CETP activity was significantly lower in HDL\(_2\) from the high tomato group compared with the low tomato group (230 ± 5.29 vs. 256 ± 8.25, \(p = 0.025\)). None of the lycopene interventions significantly affected PON-1 and LCAT activities in HDL\(_2\) (\(p = 0.484\) and \(p = 0.382\) for change from baseline, respectively, Tables 4, 7). However, PON-1 activity significantly increased by 7.8 and 7.5% in HDL\(_3\) after a high tomato diet and lycopene supplement interventions, respectively (\(p = 0.036\)). Similar results were found for PON-1 activity in serum (\(p < 0.001\), Table 7). Both interventions with lycopene diets tended to induce an increase in LCAT activity in HDL\(_3\) compared to baseline (significantly for the lycopene supplement, \(p = 0.05\)). After the 12-week intervention, CETP activity in HDL\(_2\) tended to be lower in both lycopene supplement groups compared to the low tomato group, significantly for the lycopene supplement group (\(p = 0.005\), Table 6). HDL\(_3\)-CETP activity significantly decreased after the 12-week intervention compared to baseline in both lycopene-rich groups (\(p < 0.001\) for both lycopene supplement and high tomato diet). Between-group analysis of differences in concentration changes at week 12 from baseline showed that both lycopene interventions significantly lowered HDL\(_3\)-CETP activity compared to the low tomato group (\(p = 0.002\)).

Effects of interventions on lipoprotein subclasses distribution and sizes

The HDL subclasses distribution was similar between the groups at baseline and was not affected by the intervention (Table 8). VLDL and LDL profiles also remained unchanged after intervention for all the study groups (not shown). None of the dietary interventions significantly affected the size of lipoprotein classes (Table 9).

Discussion

This is the first comprehensive study identifying a specific dietary component, lycopene, able to significantly modulate activities related to HDL functionality. Our results confirm our preliminary results showing that dietary lycopene beneficially affects PON-1 activity in serum and HDL\(_3\) (14). These changes were associated with an increase in lycopene HDL content. PON-1 is an enzyme associated with HDL, particularly HDL\(_3\) (26), which, via its proton-donating properties, inactivates peroxidized lipids removed from apolipoprotein B-containing lipoproteins (27). Our results support previous findings in a diabetic rat model, which showed that lycopene restored PON-1 activity to normal levels (28). Human trials with diets...
TABLE 3 Lycopene concentration in HDL₂, HDL₃, and serum following 12-week intervention with either a low tomato diet, lycopene supplement, or high tomato diet.

|          | N   | Baseline (U/L) | WK 12 (U/L) | Change at WK 12 (U/L) | Pre vs. post P-Value |
|----------|-----|----------------|-------------|-----------------------|---------------------|
| **Serum** |     |                |             |                       |                     |
| Low tomato diet | 76  | 57,942 (2,108) | 57,954 (2,065)
| Lycopene supplement | 68  | 52,864 (2,204) | 66,147 (3,558)
| High tomato diet | 81  | 55,552 (2,297) | 59,174 (1,742)
| Between group P-value | 0.284 | 0.053 | <0.001 |
| **HDL₂** |     |                |             |                       |                     |
| Low tomato diet | 69  | 1.88 (0.97) | 2.09 (1.12) | 0.21 (0.02, 0.41) | 0.117 |
| Lycopene supplement | 59  | 2.02 (1.80) | 2.35 (1.87) | 0.33 (−0.27, 0.93) | 0.074 |
| High tomato diet | 63  | 2.84 (2.51) | 2.59 (2.63) | −0.25 (−0.69, 0.18) | 0.005 |
| Between group P-value | 0.832 | 0.418 | 0.484 |
| **HDL₃** |     |                |             |                       |                     |
| Low tomato diet | 69  | 2.30 (1.54) | 2.25 (1.49) | −0.06 (−0.18, 0.00) | 0.240 |
| Lycopene supplement | 59  | 2.42 (1.51) | 2.50 (1.40) | 0.11 (−0.04, 0.25) | 0.162 |
| High tomato diet | 63  | 2.45 (1.44) | 2.52 (1.41) | 0.13 (−0.04, 0.29) | 0.005 |
| Between group P-value | 0.806 | 0.182 | 0.036 |

Results are mean (SEM), apart from change from baseline which are presented as mean (95% CI). Lycopene concentration is expressed as nmol/L in serum and as nmol/mg protein in HDL fractions. Differences in concentration changes at week 12. From baseline between groups were assessed by using two-factor ANOVA (p ≤ 0.05). Paired samples t-test was used to assess pre vs. post, with significance level set p ≤ 0.05. Values with different superscript letters are statistically significantly different (LSD post-hoc test).

TABLE 4 PON-1 activity in serum, HDL₂, and HDL₃ following 12-week intervention with either a low tomato diet, lycopene supplement, or high tomato diet.

|          | N   | Baseline (U/L) | WK 12 (U/L) | Change at WK 12 (U/L) | Pre Vs. post P-Value |
|----------|-----|----------------|-------------|-----------------------|---------------------|
| **SERUM** |     |                |             |                       |                     |
| Low tomato diet | 76  | 57,942 (2,108) | 57,954 (2,065)
| Lycopene supplement | 68  | 52,864 (2,204) | 66,147 (3,558)
| High tomato diet | 81  | 55,552 (2,297) | 59,174 (1,742)
| Between group P-value | 0.284 | 0.053 | <0.001 |
| **HDL₂** |     |                |             |                       |                     |
| Low tomato diet | 69  | 1.88 (0.97) | 2.09 (1.12) | 0.21 (0.02, 0.41) | 0.117 |
| Lycopene supplement | 59  | 2.02 (1.80) | 2.35 (1.87) | 0.33 (−0.27, 0.93) | 0.074 |
| High tomato diet | 63  | 2.84 (2.51) | 2.59 (2.63) | −0.25 (−0.69, 0.18) | 0.005 |
| Between group P-value | 0.832 | 0.418 | 0.484 |
| **HDL₃** |     |                |             |                       |                     |
| Low tomato diet | 69  | 2.30 (1.54) | 2.25 (1.49) | −0.06 (−0.18, 0.00) | 0.240 |
| Lycopene supplement | 59  | 2.42 (1.51) | 2.50 (1.40) | 0.11 (−0.04, 0.25) | 0.162 |
| High tomato diet | 63  | 2.45 (1.44) | 2.52 (1.41) | 0.13 (−0.04, 0.29) | 0.005 |
| Between group P-value | 0.806 | 0.182 | 0.036 |

Results are expressed as mean (SEM) apart from change at week 12 which are presented as mean (95% CI). PON-1 activity in serum and in HDL₂ and HDL₃ is expressed as U/L and U/mg protein, respectively. Differences in concentrations at baseline, week 12 and week concentration changes at week 12 from baseline between groups were assessed by using two-factor ANOVA. Paired samples t-test was used to assess pre vs post (p ≤ 0.05). Values with different superscript letters are statistically significantly different (LSD post-hoc test).

Rich in carotenoids also support our findings. In a small acute intervention, an increase in postprandial PON-1 activity concomitant to increased serum carotenoid concentrations was observed after ingestion of a Mediterranean-type meal in healthy subjects (29). Similarly, a diet rich in fruit and vegetables has been shown to increase PON-1 activity in type-2 diabetic subjects compared to a Western-style diet (30). Similar results were obtained after 1-year intervention with a traditional Mediterranean diet in people with a high risk of cardiovascular disease (31) and the authors suggested that bioactive compounds present in the diet, including carotenoids, could induce local antioxidant functions, preserve other dietary antioxidants in HDL lipoproteins, and protect PON1 against oxidative modifications or enhance its function.

Lecithin cholesterol acyltransferase (LCAT) is another enzyme closely associated with HDL₃ (32). We observed an increase in LCAT-HDL₃ after a 12-week intervention in both treatment groups, but only significant for the lycopene supplement group. Other interventions with a traditional
Nutrition

Frontiers in Nutrition

TABLE 5  LCAT activity in HDL₂ and HDL₃ following 12-week intervention with either a low tomato diet, lycopene supplement, or high tomato diet.

|          | N | Baseline (470/390) | WK 12 (470/390) | Change at WK 12 (470/390) | Pre vs. post | P-value |
|----------|---|--------------------|-----------------|---------------------------|-------------|---------|
|          |    |                    |                 |                           |             |         |
| HDL₂     |    |                    |                 |                           |             |         |
| Low tomato diet | 69 | 5.24 (0.26) | 5.28 (0.27) | 0.04 (–0.06, 0.14) | 0.919     |
| Lycopene supplement | 59 | 5.79 (0.28) | 5.85 (0.26) | 0.06 (–0.05, 0.16) | 0.161     |
| High tomato diet | 63 | 5.15 (0.26) | 5.09 (0.26) | –0.06 (–0.16, 0.04) | 0.770     |
| Between group P-value |       | 0.277            | 0.184           | 0.382                     |             |         |
| HDL₃     |    |                    |                 |                           |             |         |
| Low tomato diet | 69 | 0.37 (0.02) | 0.37 (0.02) | –0.00 (–0.01, 0.01) | 0.333     |
| Lycopene supplement | 59 | 0.37 (0.02) | 0.39 (0.02) | 0.01 (0.00, 0.02) | 0.006     |
| High tomato diet | 63 | 0.37 (0.02) | 0.38 (0.02) | 0.04 (–0.00, 0.01) | 0.123     |
| Between group P-value |       | 0.952            | 0.577           | 0.050                     |             |         |

Results are expressed as mean (SEM) apart from change at week 12 which are presented as mean (95% CI). LCAT activity in HDL₂ and HDL₃ is expressed as 470:390 ratio and 470:390 ratio/mg protein, respectively. Differences in concentration changes at week 12 from baseline between groups were assessed by using one-factor ANOVA, with post-hoc LSD. Paired samples t-test was used to assess pre vs. post, with significance level set p ≤ 0.05. Values with different superscript letters are statistically significantly different (p < 0.05).

TABLE 6  CETP activity in HDL₂ and HDL₃ following 12-week intervention with either a low tomato diet, lycopene supplement, or high tomato diet.

|          | N | Baseline | WK 12 | Change at WK 12 | Pre vs. post | P-value |
|----------|---|----------|-------|-----------------|-------------|---------|
|          |    |          |       |                 |             |         |
| HDL₂     |    |          |       |                 |             |         |
| Low tomato diet | 69 | 1.07 (0.45) | 1.08 (0.44) | 0.01 (–0.01, 0.03) | 0.382     |
| Lycopene supplement | 59 | 1.11 (0.43) | 1.04 (0.40) | –0.07 (–0.13, –0.01) | 0.004     |
| High tomato diet | 63 | 0.94 (0.45) | 0.93 (0.44) | –0.01 (–0.04, 0.01) | 0.095     |
| Between group P-value |       | 0.026            | 0.008           | 0.005                     |             |         |
| HDL₃     |    |          |       |                 |             |         |
| Low tomato diet | 69 | 2.55 (2.04) | 2.93 (2.68) | 0.39 (0.09, 0.69) | 0.714     |
| Lycopene supplement | 59 | 2.61 (2.90) | 1.84 (2.36) | –0.77 (–1.35, 0.20) | <0.001   |
| High tomato diet | 63 | 2.09 (1.82) | 1.84 (2.01) | –0.25 (–0.57, 0.08) | <0.001   |
| Between group P-value |       | 0.143            | 0.036           | 0.002                     |             |         |

Results are expressed as mean (SEM) apart from change at week 12 which are presented as mean (95% CI). CETP activity in HDL₂ and HDL₃ is expressed as µmol/L and µmol/mg protein, respectively. Differences in concentration changes at week 12 from baseline between groups were assessed by using one-factor ANOVA, with post-hoc LSD. Paired samples t-test was used to assess pre vs. post, with significance level set p ≤ 0.05. Values with different superscript letters are statistically significantly different (p < 0.05).

TABLE 7  SAA concentration in serum, HDL₂, and HDL₃ following 12-week intervention with either a low tomato diet, lycopene supplement, or high tomato diet.

|          | N | Baseline | WK 12 | Change at WK 12 | Pre vs. post | P-value |
|----------|---|----------|-------|-----------------|-------------|---------|
|          |    |          |       |                 |             |         |
| Serum    |    |          |       |                 |             |         |
| Low tomato diet | 76 | 18,005 (15,307) | 20,461 (19,982) | 2456 (–494, 5407) | 0.192 |
| Lycopene supplement | 68 | 17,095 (16,465) | 14,277 (15,355) | –2,819 (–5,326, –310) | 0.029 |
| High tomato diet | 81 | 15,258 (13,644) | 15,337 (14,205) | 79 (–2,514, 2,671) | 0.656 |
| Between group P-value |       | 0.605            | 0.097           | 0.046                     |             |         |
| HDL₂     |    |          |       |                 |             |         |
| Low tomato diet | 69 | 2.84 (2.51) | 2.59 (2.63) | –0.25 (–0.69, 0.18) | 0.113 |
| Lycopene supplement | 59 | 3.02 (2.77) | 2.90 (3.97) | –0.12 (–0.97, 0.74) | 0.725 |
| High tomato diet | 63 | 2.84 (2.51) | 2.59 (2.63) | –0.25 (–0.69, 0.18) | 0.195 |
| Between group P-value |       | 0.676            | 0.300           | 0.221                     |             |         |
| HDL₃     |    |          |       |                 |             |         |
| Low tomato diet | 69 | 2.55 (2.04) | 2.93 (2.68) | 0.39 (0.09, 0.69) | 0.001 |
| Lycopene supplement | 59 | 2.61 (2.90) | 1.84 (2.36) | –0.77 (–1.35, 0.20) | 0.009 |
| High tomato diet | 63 | 2.09 (1.82) | 1.84 (2.01) | –0.25 (–0.57, 0.08) | 0.092 |
| Between group P-value |       | 0.372            | 0.039           | <0.001                     |             |         |

Results are expressed as mean (SEM) apart from change at week 12 which are presented as mean (95% CI). SAA concentration is expressed as µg/L in serum and as µg/mg protein in HDL fractions. Differences in concentration changes at week 12 from baseline between groups were assessed by using two-factor ANOVA. Paired samples t-test was used to assess pre vs post (p ≤ 0.05). Values with different superscript letters are statistically significantly different (LSD post-hoc test).
Mediterranean diet or diet rich in fruit and vegetable has also shown improvement in LCAT activity (30, 33). An increase in LCAT activity would provide health benefits, considering that LCAT, and being involved in the maturation of HDL in the reverse cholesterol transport process (34), also functions as an antioxidant by accepting/donating protons via its active serine residue and is able to scavenge and neutralize free radicals that have been removed by HDL from LDL. LCAT is very sensitive to oxidative attacks (35) and lycopene may contribute to maintaining LCAT as non-oxidized and functional. Lycopene, through its ability to quench free radicals as an antioxidant by accepting/donating protons via the reverse cholesterol transport process, overall increasing LCAT’s anti-antioxidant activity. Daniels et al. (36) could donate electrons to LCAT, and therefore recycling LCAT’s proton-donating site, thus increasing LCAT’s anti-antioxidant activity. Daniels et al. (30) suggested that a carotenoid-enrichment in HDL could be responsible for the increase in activity of LCAT in HDL3 observed in subjects with type 2 diabetes following a high fruit and vegetable diet.

Cholesterol ester transfer protein (CETP) plays a central role in cholesterol transfer from HDL to triglyceride-poor lipoproteins, and subsequently to the liver, and CETP activity is often increased in high-cardiovascular-risk states (ref). Therefore, the decrease in HDL2-CETP after lycopene supplementation (~5.5%) and the decrease in HDL3-CETP activity after intervention with a high tomato and a lycopene supplement (~5.9 and ~6.9%, respectively) could be protective, as it may contribute to maintaining HDL homeostatic function.

Unfortunately, we were unable to measure CETP activity in serum. However, it is likely that we would have observed a similar trend as CETP is majorly associated with HDL (37). Other interventions with carotenoid-rich diets showed reductions in HDL3-CETP activity in hypertensive subjects and in HDL2-CETP activity in elderly subjects (38).

Table 8: HDL subclass distribution in response to 12-week intervention with high tomato, lycopene, and control diets.

|                | High tomato | Lycopene | Low tomato |
|----------------|-------------|----------|-----------|
|                | n = 81      | n = 68   | n = 76    |
| HDL particles (Total) |             |          |           |
| Baseline       | 32.7 (31.5, 33.8) | 31.6 (30.4, 32.7) | 31.1 (30.2, 32.1) | 0.117 |
| (µmol/L) Wk12  | 32.5 (31.4, 33.5) | 31.7 (31.5, 33.0) | 31.8 (30.8, 32.9) | 0.258 |
| Large HDL particles | 8.8 (7.8, 9.7)  | 8.3 (7.4, 9.3)  | 8.5 (7.7, 9.4)  | 0.819 |
| (µmol/L) Wk12  | 8.6 (7.7, 9.5)  | 8.3 (7.4, 9.3)  | 8.7 (7.9, 9.5)  | 0.701 |
| Medium HDL particles | 3.7 (2.9, 4.5)  | 3.1 (2.3, 4.0)  | 3.1 (2.2, 4.0)  | 0.542 |
| (µmol/L) Wk12  | 3.7 (2.9, 4.4)  | 3.7 (2.5, 4.8)  | 3.1 (2.4, 3.8)  | 0.535 |
| Small HDL particles | 20.2 (18.9, 21.6) | 20.1 (19.0, 21.3) | 19.5 (18.3, 20.8) | 0.706 |
| (µmol/L) Wk12  | 20.1 (18.8, 21.5) | 19.8 (18.4, 21.0) | 20.1 (18.9, 21.2) | 0.398 |

Table 9: Lipoprotein size in response to 12-week intervention with high tomato, lycopene, and control diets.

|                | High tomato | Lycopene | Control |
|----------------|-------------|----------|---------|
|                | n = 81      | n = 68   | n = 76  |
| VLDL size (nm) |             |          |         |
| Baseline       | 49.20 (1.28) | 46.99 (1.00) | 48.42 (1.07) | 0.935 |
| Wk12b          | 48.97 (0.98) | 50.00 (1.95) | 49.30 (1.10) | 0.865 |
| LDL size (nm)  |             |          |         |
| Baseline       | 21.50 (0.82) | 21.32 (0.96) | 21.40 (0.87) | 0.356 |
| Wk12           | 21.44 (0.81) | 21.40 (0.97) | 21.43 (0.95) | 0.931 |
| HDL size (nm)  |             |          |         |
| Baseline       | 9.20 (0.06) | 9.21 (0.07) | 9.24 (0.06) | 0.892 |
| Wk12           | 9.21 (0.06) | 9.20 (0.07) | 9.26 (0.06) | 0.785 |

*Data are the mean (SEM).

*Differences at baseline were assessed by using one-factor ANOVA on log-transformed values.

*Differences in concentration changes at week 6 from baseline between groups were assessed by using one-factor ANOVA.

*Median, interquartile range in parentheses (all such values).

Table 8: HDL subclass distribution in response to 12-week intervention with high tomato, lycopene, and control diets.

|                | High tomato | Lycopene | Low tomato |
|----------------|-------------|----------|-----------|
|                | n = 81      | n = 68   | n = 76    |
| HDL particles (Total) |             |          |           |
| Baseline       | 32.7 (31.5, 33.8) | 31.6 (30.4, 32.7) | 31.1 (30.2, 32.1) | 0.117 |
| (µmol/L) Wk12  | 32.5 (31.4, 33.5) | 31.7 (31.5, 33.0) | 31.8 (30.8, 32.9) | 0.258 |
| Large HDL particles | 8.8 (7.8, 9.7)  | 8.3 (7.4, 9.3)  | 8.5 (7.7, 9.4)  | 0.819 |
| (µmol/L) Wk12  | 8.6 (7.7, 9.5)  | 8.3 (7.4, 9.3)  | 8.7 (7.9, 9.5)  | 0.701 |
| Medium HDL particles | 3.7 (2.9, 4.5)  | 3.1 (2.3, 4.0)  | 3.1 (2.2, 4.0)  | 0.542 |
| (µmol/L) Wk12  | 3.7 (2.9, 4.4)  | 3.7 (2.5, 4.8)  | 3.1 (2.4, 3.8)  | 0.535 |
| Small HDL particles | 20.2 (18.9, 21.6) | 20.1 (19.0, 21.3) | 19.5 (18.3, 20.8) | 0.706 |
| (µmol/L) Wk12  | 20.1 (18.8, 21.5) | 19.8 (18.4, 21.0) | 20.1 (18.9, 21.2) | 0.398 |

*Differences at baseline were assessed by using one-factor ANOVA on log-transformed values.

*Differences in concentration changes at week 12 from baseline between groups were assessed by using one-factor ANOVA.
the lycopene supplement and high tomato groups, respectively, while HDL3-SAA significantly increased following consumption of a low tomato diet. This suggests that increased lycopene intake beneficially lowers SAA-related inflammation. Like PON-1 and LCAT, SAA is particularly associated with HDL4 (39), therefore, any effects would be less readily identifiable in HDL2, which explains the lack of significant effect of the intervention observed in that particular HDL subfraction. SAA is an acute-phase protein that associates with HDL, rendering these particles dysfunctional, with reduced reverse transport of cholesterol (40), antioxidant (41), and anti-inflammatory (26) capabilities. Therefore, reducing SAA HDL content may be beneficial for HDL functionality. However, SAA renders HDL dysfunctional during a severe inflammatory response, when SAA can become the main apolipoprotein present on HDL (42) and the changes in SAA content might only be an indication of lycopene anti-inflammatory effects, and not related to HDL functionality. Lycopene has the ability to minimize the production and secretion of SAA from the liver and adipocytes (43, 44), which reduces systemic and HDL-related inflammation (44), which might explain the results observed.

The effects on HDL functionality and SAA observed were not associated with changes in HDL2 and HDL3 apoA1 content, which remained unchanged after intervention in all the groups (results not shown). This is in contradiction with previous findings reporting a significant increase in apoA1 concentration in subjects with type 2 diabetes who had consumed 200 g of raw tomatoes daily for 8 weeks (45). SAA concentration is inversely associated with apoA1 concentration (26, 46) while no change in apoA1 concentration following a reduction in SAA has also been reported (30). It is possible that apoA1 may have been redistributed within the HDL particles, thus meaning that there was no overall net change in apoA1 concentration. HDL can carry different numbers of apoA1 molecules (27), therefore, the loss of SAA from one specific HDL particle may allow apoA1 to be redistributed to another HDL particle, without changing the overall apoA1 HDL concentration.

The changes observed were also not associated with a concomitant change in lipoprotein subclass distribution and size. To our knowledge, this is the first time the effects of dietary lycopene on lipoprotein subclass distribution and size have been described. Carotenoids, including lycopene, circulate in the plasma bound to lipoproteins, and despite the significant enrichment in lycopene concentration both in serum and HDL, the particle subclasses and sizes remained unchanged. Results from subcohorts of the PREDIMED trial using NMR (47) or Lipoprint technology (31) showed an increase in large LDL/HDL and HDL fractions, respectively, after intervention with a Mediterranean diet in a population at high cardiovascular risk. However, our dietary interventions were minimal in comparison, and carried out on healthier subjects.

The main strengths of this study were excellent compliance, low dropout rates, and a relatively large sample size (n = 225) and appropriate comparators (low and high tomato diets and low tomato diets with lycopene supplement). Tomatoes are also rich in other phytochemicals and minerals which may potentially also alter HDL function and SAA content. However, the effects being more pronounced and predominant in the lycopene group compared with the high tomato diet strongly suggest that lycopene was responsible for improving HDL functionality and decreasing HDL-associated SAA content. The lycopene supplementation level and the dietary intervention were physiologically relevant and perfectly achievable. To our knowledge, no previous trial compared appropriately a lycopene supplement with a high-tomato diet, using an appropriate control arm. We measured the activities of three key enzymes (CETP, PON-1, and LCAT) and an inflammatory marker associated with HDL (SAA). However, we could not assess fully all aspects of HDL functionality, such as HDL cholesterol efflux capacity. We could also not determine the HDL mass content of the enzymes, and CETP and LCAT activities in serum. Further studies, namely, full HDL lipidomic and proteomic profile, are warranted to investigate the mechanisms by which dietary lycopene improves HDL function and whether these properties convey cardio protective effects.

### Data availability statement

The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.

### Ethics statement

The studies involving human participants were reviewed and approved by North of Scotland Research Ethics Committee (07/S0801/32). The patients/participants provided their written informed consent to participate in this study.

### Author contributions

FT designed the randomized controlled trial and drafted the article. FT and JM designed lipoprotein and high-density lipoprotein experiments. JM and JW supervised S-LH. AR and NV conducted the trial. S-LH, AR, NV, and SM conducted laboratory analyses. S-LH, FT, JM, and JW analyzed data. All authors read and approved the final manuscript.

### Funding

This research was commissioned by the Food Standards Agency (grant number No. 2038) and funded by the Policy
Acknowledgments

We gratefully acknowledge all volunteers who participated in the study.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

1. Sesso HD, Liu S, Gaziano JM, Buring JE. Dietary lycopene, tomato-based food products and cardiovascular disease in women. J Nutr133 (2003) 2356–61. doi: 10.1093/jn/133.7.2356
2. Jacques PF, Lyass A, Massaro JM, Vasan RS, D’Agostino RB, Sr. Relationship of lycopene intake consumption of tomato products to incident CVD. Br J Nutr. (2013) 110:545–51. doi: 10.1017/s0007114512005417
3. Mazidi M, Katski N, George ES, Banach M. Tomato and lycopene consumption is inversely associated with total and cause-specific mortality: a population-based cohort study, on behalf of the international lipid expert panel (ILEP). Br J Nutr. (2020) 124:1633–40. doi: 10.1017/S0007114519002150
4. Xu X, Li S, Zhu Y. Dietary intake of tomato and lycopene and risk of all-cause and cause-specific mortality: results from a prospective study. Front Nutr. (2021) 8.684859. doi: 10.3389/fnut.2021.684859
5. Saini RK, Rengasamy KRR, Mahomoodally FM, Keum YS. Protective effects of lycopene in cancer, cardiovascular, and neurodegenerative diseases: an update on epidemiological and mechanistic perspectives. Pharmacol Res. (2020) 155:104730. doi: 10.1016/j.phrs.2020.104730
6. Petyaev IM, Dovgalevsky PY, Chelykov VA, Chalyk NE, Pristensky DV, Chernyshova MP, et al. Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary artery disease. Food Sci Nutr. (2018) 6:1770–7. doi: 10.1002/fsn3.734
7. Cheng HM, Koutsidis G, Lodge JK, Ashor A, Siervo M, Lara J, et al. Tomato and lycopene supplementation and cardiovascular risk factors: a systematic review and meta-analysis. Atherosclerosis. (2017) 257:100–8. doi: 10.1016/j.atherosclerosis.2017.01.009
8. Li H, Chen A, Zhao L, Bhagavatula AS, Rahman I, et al. Effect of tomato consumption on fasting blood glucose and lipid profiles: a systematic review and meta-analysis of randomized controlled trials. Phytother Res. (2020) 34:1956–65. doi: 10.1002/ptr.6660
9. Valderas-Martinez P, Chiva-Blanch G, Casas R, Arranz S, Martinez-Huelamo M, Urip-Sarda, et al. Tomato sauce enriched with olive oil exerts greater effects on cardiovascular disease risk factors than raw tomato and tomato sauce: a randomized trial. Nutrients. (2016) 8:170. doi: 10.3390/nu8030170
10. Gajendragadkar PR, Hubich A, Maki-Petaja KM, Serg M, Wilkinson IB, Cherian J, et al. Effects of oral lycopene supplementation on vascular function in patients with cardiovascular disease and healthy volunteers: a randomised controlled trial. PLoS ONE. (2014) 9:e99070. doi: 10.1371/journal.pone.0099070
11. Arranz S, Martinez-Huelamo M, Valleveda Quraitel A, Valderas-Martinez P, Illan M, Sacanella E, et al. Influence of olive oil on carotenoid absorption from tomato juice and effects on postprandial lipemia. Food Chem. (2015) 168:203–10. doi: 10.1016/j.foodchem.2014.07.053
12. Tierney AC, Rumble CE, Billings LM, George ES. Effect of dietary and supplemental lycopene on cardiovascular risk factors: a systematic review and meta-analysis. Adv. Nutr. (2020) 11:53–88. doi: 10.1093/advances/nmaa069
13. Thies F, Masson LE, Rudd A, Vaughan N, Tsang C, Brettenden J, et al. Effect of a tomato-rich diet on markers of cardiovascular disease risk in moderately overweight, disease-free, middle-aged adults: a randomized controlled trial. Am J Clin Nutr. (2012) 95:13–22. doi: 10.3945/ajcn.111.262866
14. McEneny J, Wade L, Young IS, Masson L, Duthie G, McGinty A, et al. Lycopene reduces inflammation and improves HDL functionality in moderately overweight middle aged individuals. J Nutr Biochem. (2013) 24:3–168. doi: 10.1016/j.jnutbio.2012.03.015
15. Movva IR, Rader D. Laboratory assessment of HDL, heterogeneity and function. Clin Chem. (2008) 54:886–880. doi: 10.1373/clinchem.2007.01923
16. Karlsson H, Kontush A, James RW. Functionality of HDL, antioxidant and detoxifying effects. Handb Exp Pharmacol. (2015) 224:207–28. doi: 10.1007/978-3-642-49665-0_5
17. Ayl RJ, Marsche G, Lestavel S, Sattler W, Malle E, Ayub A, et al. Role of serum amyloid A during metabolism of acute-phase HDL, by macrophages. Arterioscler Thromb Vasc Biol. (2000) 20:763–72. doi: 10.1161/01.ATV.20.3.763
18. Khovdahuntsuk W, Kim MS, Memon RA, Shigenaga JK, Moser AH, F Stingold KR, et al. Effects of infection and inflammation on lipid and lipoprotein metabolism: mechanisms and consequences to the host. J Lipid Res. (2004) 45:1169–96. doi: 10.1194/jlr.R300009-JLR200
19. Kappelle PJ, Bijzet J, Hazenberg BP, Dullaart RP. Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res. (2011) 42:219–25. doi: 10.1016/j.arcmed.2011.05.002
20. Eren E, Yilmaz N, Aydin O. High density lipoprotein and its dysfunction. Open Biochem J. (2012) 6:78–93. doi: 10.2174/1874091X12610060078
21. Schulze KE, Altman DG, Moher D, Group CONSORT. CONSORT 2010 Statement: Updated Guidelines for Reporting Parallel Group Randomised Trials. PLoS Med. (2010) 7, e1000251. doi: 10.1371/journal.pmed.1000251
22. McPherson PA, Young IS, McKibben R, McEneny J. High density lipoprotein subfractions: isolation, composition, and their duplicitous role in oxidation. J Lipid Res. (2007) 48:86–95. doi: 10.1194/jr.0600094-JLR200
23. Craft NE. Carotenoid reversed-phase high-performance liquid chromatography methods: reference compendium. Methods Enzymol. (1992) 213:185–203. doi: 10.1016/0076-6879(92)21312-1D
24. McPherson PA, Young IS, McEneny J. A dual role for lecithin cholesterol acyltransferase (EC 2.3.1.43) in lipid oxidation. Free Radic Biol Med. (2007) 43:1484–93. doi: 10.1016/j.freeradbiomed.2007.08.007
25. Haselwanter O, Savage DA, McMaster D, Loughrey CM, McNamer FT, Middleton D, et al. Paraoxonase polymorphisms are not associated with cardiovascular risk in renal transplant recipients. Kidney Int. (1999) 56:289–98. doi: 10.1046/j.1523-1755.1999.00521.x
26. Kontush A, Chapman MJ. Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Res. (2008) 58:3. doi: 10.1124/pr.58.3.1
27. Kentush A, Chantepe, Chapman MJ. Small, dense HDL particles exert potent protection of atherogenic LDL against oxidative stress. *Arterioscler Thromb Vasc Biol.* (2003) 23:1881–8. doi: 10.1161/01.ATV.0000091338.93232.E8

28. Yegin SC, Yur E, Ceylan E. Effect of lycopene application in rats with experimental diabetes using lipoprotein, paraoxonase and cytokines. *J Memb Biol.* (2013) 246:621–6. doi: 10.1007/s00232-013-9575-2

29. Blum A, Monir M, Khazim K, Peleg A, Blum N. Tomato-rich (Mediterranean) diet does not modify inflammatory markers. *Clin Invest Med.* (2007) 30:2.E70–E74. doi: 10.2501/cim.v30i2.982

30. Danieja IA, Mulligan C, McCance D, Woodsides J, Patterson C, Young IS, et al. A randomised controlled trial of increasing fruit and vegetable intake and how this influences the carotenoid concentration and activities of PON-1 and LCAT in HDL from subjects with type 2 diabetes. *Cardiovasc. Diabetol.* (2014) 13:13–6. doi: 10.1186/1475-2840-13-16

31. Hernández A, Castaño O, Elosua R, Pintó X, Estruch R, Salas-Salvadó J, et al. Mediterranean diet improves high-density lipoprotein function in high-cardiovascular-risk individuals. *Circulation.* (2017) 135:633–43. doi: 10.1161/CIRCULATIONAHA.116.023712

32. Höckerstedt A, Tikkkanen MJ, Jauhiainen M. LCAT facilitates transacylation of 17 beta-estradiol in the presence of HDL3 subfraction. *J Lipid Res.* (2000) 41:392–7. doi: 10.1016/S0022-2275(20)30145-0

33. Hernández A, Farrás M, Pitó M. Olive oil phenolic compounds and high-density lipoprotein function. *Curr Opin Lipidol.* (2016) 27:47–53. doi: 10.1097/MOL.0000000000000261

34. Navab M, Reddy ST, Van Lenten BJ, Anantharamaiah GM, Fogelman AM. The role of dysfunctional HDL in atherosclerosis. *J Lipid Res.* (2009) 50:S145–9. doi: 10.1194/jlr.R800036-JLR200

35. Wang K, Subbaiah PV. Importance of the free sulfhydryl groups of lecithin-cholesterol acyltransferase for its sensitivity to oxidative inactivation. *Biochim Biophys Acta.* (2000) 1488:268–77. doi: 10.1016/S0168-1881(00)00130-X

36. Kong KW, Kho O, Prasad KN, Ismail A, Tan CP, Rajab NF, et al. Revealing the power of the natural red pigment lycopene. *Molecules.* (2010) 15:2.59–87. doi: 10.3390/molecules15020959

37. Qiu X, Mistry A, Ammirati MJ, Chrumpik BA, Clark RW, Cong Y, et al. Crystal structure of cholesteryl ester transfer protein reveals a long tunnel and four bound lipid molecules. *Nat Struct Mol Biol.* (2007) 14:106–13. doi: 10.1038/nsmb1197

38. Nadeem N, Woodsides J, Neville CE, McCall DO,McCance D, Edgar D, et al. Serum amyloid A-related inflammation is lowered by increased fruit and vegetable intake, while high-sensitive C-reactive protein, IL-6 and E-selectin remain unresponsive. *Br J Nutr.* (2014) 112:1129–36. doi: 10.1017/S00071145140101639

39. Uhlar CM, Whitehead A, Serum amyloid A, the major vertebrate acute-phase reactant. *Eur J Biochem.* (1999) 265:501–23. doi: 10.1046/j.1432-1327.1999.00657.x

40. Marsche G, Frank S, Raynes JG, Kozaryski KE, Sattler W, Malle E, et al. The lipidation status of acute-phase protein serum amyloid A determines cholesterol mobilization via scavenger receptor class B, type I. *Biochem J.* (2007) 402:117–24. doi: 10.1042/BJ20061406

41. Marsche G, Saemmann MD, Heinemann A, Holzer M. Inflammation alters HDL composition and function: implications for HDL-raising therapies. *Pharmacol Ther.* (2013) 137:341–51. doi: 10.1016/j.pharmthera.2012.12.001

42. Webb NR. High-Density Lipoproteins and serum amyloid A (SAA). *Curr Atheroscler Rep.* (2021) 23:2. doi: 10.1007/s11883-020-00991-4

43. Dallinga-Thie GM, Fransen R, Moonj HL, Visscher ME, Hassing HC, Peelman E, et al. The metabolism of triglyceride-rich lipoproteins revisited: new players, new insight. *Atherosclerosis.* (2010) 211:1–8. doi: 10.1016/j.atherosclerosis.2009.12.027

44. Gouranton E, Thabuis C, Rioslet C, Mazet-Demoulin C, El Yazidi C, Amiot MJ, et al. Lycopene inhibits pro-inflammatory cytokine and chemokine expression in adipose tissue. *J Nutri Biochem.* (2011) 22:642–8. doi: 10.1016/j.jnutbio.2010.04.016

45. Shidfar F, Frogshafar N, Vafa M, Rajab A, Hosseini S, Shidfar S, et al. The effects of tomato consumption on serum glucose, apolipoprotein B, apolipoprotein A-I, homocysteine and blood pressure in type 2 diabetic patients. *Int J Food Sci Nutr.* (2012) 63:289–94. doi: 10.3109/09637486.2010.529072

46. de Beer MC, Webb NW, Wroblewski JM, Noftskier VP, Rateri DL, et al. Impact of serum amyloid A on high density lipoprotein composition and levels. *J Lipid Res.* (2010) 51:3117–25. doi: 10.1194/jlr.M005413

47. Damasceno NR, Sala-Vila A, Coñán M, Pérez-Heras AM, Fitó M, Ruiz-Gutiérrez V, et al. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. *Atherosclerosis.* (2013) 230:2.347–53. doi: 10.1016/j.atherosclerosis.2013.08.014